Navigation Links
Take a Break Inbetween Exercise

xygen intake.

The recovery and rest periods were conducted while the subjects sat in chairs. Blood samples were taken every 15 minutes during the exercise and every 30 minutes during the recovery period. Their respiratory gas and heart rates were monitored continuously throughout the trial.

Summary of Results The Repeated trial showed a greater amount of lipolysis (fat breakdown) than did the Single trial. This Repeated trial also had a pronounced increase in free fatty acids and glycerol (chemical compounds that are released when stored fat is used) concentrations in the final 15 minutes of exercise, whereas these concentrations only progressively increased throughout the Single trial.

Also, the second half of the Repeated trial showed a significantly greater epinephrine response while also having a rapid decrease in insulin concentration as a result of lower plasma glucose.

This combination of high epinephrine and low insulin concentration may have also increased the lipolysis. There was also enhanced fat oxidation in the recovery period of the Repeated trial than in the Single trial, but this result may be because the free fatty acids concentration was already high before the recovery period.

Conclusions The American College of Sports Medicine recommends moderate exercise for the duration of 45 to 60 minutes to ensure a sufficient amount of energy is depleted in obese individuals. This has caused a greater focus on extending exercise sessions in order to burn more fat.

However, this study shows that this method may not be the most effective way to enhance fat metabolism, as splitting up a long bout of exercise with a rest period burns more fat than a continuous bout of exercise.

This study could help with the practical application of implementing new exercise methods in order to better manage and control weight in individuals in the future. However,
'"/>




Page: 1 2 3

Related medicine news :

1. Sperm washing helps couples – Breakthrough in focu
2. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
3. Breakfast improves memory
4. Breakthrough in eye treatment
5. Breaking up Dangerous Clots
6. Skip Breakfast, Get Fat
7. Genetic Breakthrough in Common Eye Problem
8. Breakthrough in cancer therapy
9. Breakthrough in Type II Diabetes
10. Breakthrough In Stem Cell Work
11. A Likely Breakthrough For Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Take Break Inbetween Exercise

(Date:12/1/2008)...ARLOTTE, N.C., Dec. 1 I..., Emeka Okafor, will be launching a mobile textin...can Lives Initiative (OMALI), a program of the Saf... the Initiative is to save one million lives in Af... blood testing kits and clinical training. , ...
(Date:12/1/2008)...NTA MONICA, Calif., Dec. 1 TOMS Sh...ched a holiday campaign online at TOMSshoes.com,...s holiday season. For 30,days, from November 20th...oppers to help give 30,000 pairs of shoes to child...ease that is 100% preventable by wearing shoes. By...
(Date:12/1/2008)..., , , , Ideas from U-M physician inc..., Mich., Dec. 1 A bottl...e are all quick and easy gifts to buy and wrap for...ot give something more healthy and beneficial to a... , Staying healthy around the holidays can be ...
(Date:12/1/2008)... JOLLA, Calif., Dec. 1 TorreyPines...nced that oral administration of NGX426, an,AMPA/...trated a statistically,significant reduction in s...d,pain state) and allodynia (pain resulting from ...d to placebo following intradermal injections of c...
Breaking Medicine News(10 mins):Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5
...als a new immune defense mechanism in normal airwa...ibrosis (CF) are particularly susceptible to bacte...the way to new approaches for treating the disease...enerate and use reactive oxygen species (ROS) to d...
...teroid, can prevent skin abnormalities induced by ...m the December //issue of the American Journal of ... Physiology. The new study also shows how psycholo...d initiate or worsen skin disorders such as psoria...
...g women who grow up in cities or move there from r...// Princess Diana was known to suffer from this e... in the country, and moved to London as a teenager...der in which young women get trapped in a routine ...
...e Family Restaurant at Lloydminister, has tested p...by a virus and affects the liver and causes fever,...iscomfort followed by yellow jaundice a few days l...ion of this virus from the worker to patrons of th...
Other Medicine News:Health News:Newly Discovered Immune Defense May Be Impaired In CF Airways 2Health News:Blocking Glucocorticoid Prevents Stress-Induced Skin Abnormalities 2Health News:Blocking Glucocorticoid Prevents Stress-Induced Skin Abnormalities 3
(Date:11/28/2008)...ll/ -- Eli Lilly and Company,(NYSE: LLY ) has w...DA) from,the U.S. Food and Drug Administration (F...gement of chronic pain. Lilly plans to resubmit th...ata from a recently completed positive study,in c...he decision does not affect duloxetine,s FDA-appro...
(Date:11/25/2008)... , Audio and Web Video Resources to accompan... Blog. Please see the bottom of this release for d... A Mayo Clinic study sho...re having a stroke -- and as a result -- delay see...findings appear in the current issue of Emergency ...
(Date:11/25/2008)...rstCall/ -- Pharmacyclics, Inc.,(Nasdaq: PCYC )...Phase 1,clinical trial with PCI-27483, the compan...IIa inhibitor. The trial was conducted in sixteen ...d pharmacologic effect of,PCI-27483. A single adm...,response in the International Normalized Ratio (...
(Date:11/24/2008)...stCall/ -- Leaders of Schering-Plough Corporation ...ors on the company,s research pipeline, highlighti...6 new entities in clinical trials or under regulat... "Research and development is adding strength an...ansformation," said Fred Hassan, chairman and CEO....
Breaking Medicine Technology:Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Silent streams 3F Escalating endangerment for North American freshwater fish 4797 1Silent streams 3F Escalating endangerment for North American freshwater fish 4797 2Silent streams 3F Escalating endangerment for North American freshwater fish 4797 3Med School Diversity May Help Whites Care Better for Minorities 26203 1Med School Diversity May Help Whites Care Better for Minorities 26203 2Med School Diversity May Help Whites Care Better for Minorities 26203 3Young African American Males Face Mental Health Crisis 3B Experts Call For New Treatment Strategies and Better Access to Care 26199 1Young African American Males Face Mental Health Crisis 3B Experts Call For New Treatment Strategies and Better Access to Care 26199 2Young African American Males Face Mental Health Crisis 3B Experts Call For New Treatment Strategies and Better Access to Care 26199 3Medco CEO Unveils Pragmatic Blueprint for Health Care Reform 3B Reducing Costs by Upwards of 241 Trillion 26195 1Medco CEO Unveils Pragmatic Blueprint for Health Care Reform 3B Reducing Costs by Upwards of 241 Trillion 26195 2Medco CEO Unveils Pragmatic Blueprint for Health Care Reform 3B Reducing Costs by Upwards of 241 Trillion 26195 3Medco CEO Unveils Pragmatic Blueprint for Health Care Reform 3B Reducing Costs by Upwards of 241 Trillion 26195 4
...ata being presented today at Digestive Disease Wee...- Microbia today,announced the presentation of dat...rated colonic transit and improved bowel function,...le bowel syndrome,(IBS-C). These data also showed ...e of adverse events. Linaclotide is a first-in-cla...
...HEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Anti...nal follow-up data on the,company,s Phase 3 invest...(vitespen). The end-of-study results, which reflec... that in a substantial,subset of patients (n = 362...ophage demonstrated a clinically significant,impro...
Other Medicine Technology:Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 2Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 2Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 3Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 4Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 5Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free,Survival by 45 Percent in Patients With Intermediate-Risk Kidney,Cancer 6
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. St
...Medication Delivery., ,Designed for adolescent an... an additional lumen and injection port for rapid ...hree endotracheal tubes designs which allow for CO...livery without additional adaptors., ETCO2™ ...
...otracheal Instillation of Topical Anesthetic, ,De...cuffed tube incorporates an additional lumen and i...sthetic above and below the cuff., ,SHERIDAN offe...r CO2 monitoring, pressure monitoring or medicatio...
...oring Lumen., ,Designed for neonatal and pediatri...tube incorporates a monitoring lumen within the wa...er lock connector bonded to lumen line provides co...onitoring or syringe irrigation of medication., ,...
Medicine Products: